OncoMatch/Clinical Trials/NCT06580002
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Is NCT06580002 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies Riluzole for breast cancer.
Treatment: Riluzole — This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels in cancer survivors (recently completing prior treatment regimens) or patients who have received whole brain radiation for benign or malignant tumors with cancer related cognitive impairment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Sarcoma
Gastric Cancer
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Head and Neck Squamous Cell Carcinoma
Colorectal Cancer
Ovarian Cancer
Hepatocellular Carcinoma
Renal Cell Carcinoma
Prostate Cancer
Urothelial Carcinoma
Testicular Germ Cell Tumor
Penile Carcinoma
Endometrial Cancer
Cervical Cancer
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Multiple Myeloma
Pancreatic Cancer
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Glioblastoma
Melanoma
Lab requirements
Liver function
AST or ALT ≥ 3x upper limit normal (ULN) excluded
Hepatic impairment as indicated by: AST or ALT ≥ 3x upper limit normal (ULN)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Chao Family Comprehensive Cancer Center, University of California Irvine · Orange, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06580002 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages